Quarterly ResultMay 11, 2026, 04:12 PM
SCYNEXIS Q1 Net Loss $(21.3)M; Acquires SCY-770 Assets; Raises $24M
AI Summary
SCYNEXIS reported a net loss of $(21.299) million for the first quarter of 2026, a significant increase from $(5.391) million in Q1 2025. Strategically, the company acquired Poxel SA's direct AMP kinase activator program assets, including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), for an $8.0 million upfront payment. To support its operations and new programs, SCYNEXIS completed a private placement in March 2026, raising $24.020 million from common stock and pre-funded warrants, leading to an increase in cash and cash equivalents to $36.671 million.
Key Highlights
- Acquired Poxel SA's direct AMP kinase activator program assets, including SCY-770, for an $8.0 million upfront payment.
- Completed March 2026 Private Placement, raising $24.020 million from common stock and pre-funded warrants.
- Reported Q1 2026 net loss of $(21.299) million, compared to $(5.391) million in Q1 2025.
- Cash and cash equivalents increased to $36.671 million as of March 31, 2026, from $21.259 million at Dec 31, 2025.
- Research and development expenses increased to $12.351 million in Q1 2026 from $5.141 million in Q1 2025.
- Selling, general and administrative expenses rose to $4.588 million in Q1 2026 from $3.726 million in Q1 2025.
- Total liabilities increased to $36.319 million as of March 31, 2026, from $9.651 million at Dec 31, 2025.
- Warrant liabilities fair value adjustment resulted in a $5.249 million loss in Q1 2026.